Clinical Trial Results:
A 6-week International, Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study to Evaluate the Feasibility of Switching from Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate (400 to 800 mg/day) in Outpatients with Schizophrenia
Summary
|
|
EudraCT number |
2004-000912-13 |
Trial protocol |
FI HU LT ES EE LV IT |
Global completion date |
09 Mar 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
15 Dec 2016
|
First version publication date |
12 Aug 2016
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
CSR-D1444C00146 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.